In the Phase 2 trials, the most common adverse events were gastrointestinal. In the MASH trial, nausea affected 66% of survodutide recipients versus 23% on placebo, diarrhea 49% versus 23%, and vomiting 41% versus 4%. In the obesity trial, roughly three-quarters of survodutide recipients reported gastrointestinal events.[1][2]
Reviewed for accuracy · Last reviewed July 8, 2026These effects were generally dose-related and tended to cluster during the escalation phase. Because survodutide is investigational, its longer-term safety profile in humans is not yet well characterized, and there is no approved label documenting rarer risks. The hedged reading is that the short-term profile resembles other incretin-based peptides, but the evidence base is still limited to Phase 2 and early Phase 3 data.
Gastrointestinal effects often ease as the body adjusts. Holding a dose steady before the next step-up and injecting after a lighter meal are commonly discussed ways to limit nausea.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Survodutide is investigational. Talk to a doctor before starting any compound.